Cannabinol — The Sunlight Experiment

Pharmacology & Research

Cannabinol is not really made by the plant so much as left behind by it: CBN forms as THC oxidises with exposure to air, light and heat, so aged or poorly stored cannabis is higher in it. It’s a weak partial agonist at CB1 and at most mildly intoxicating ^{4Reference 4Pertwee RG · 2008ReviewThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin — reviewView study →}. Its commercial identity is “the sleep cannabinoid” — but that reputation runs well ahead of the evidence, and pinning down a real hypnotic effect for CBN alone is the central research question here.

What the evidence supports

One small human trial: 20 mg CBN nightly modestly reduced sleep disturbance versus placebo — an industry-funded RCT on self-reported measures, with adding CBD giving no extra benefit ^{1Reference 1Bonn-Miller MO et al. · 2024RCTA double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human)View study →}.
Objective animal data: in rats, CBN increased sleep but biphasically (suppression first, then more sleep), and the effect appears driven substantially by its active metabolite 11-hydroxy-CBN acting at CB1 ^{2Reference 2Arnold JC et al. · 2025AnimalA sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography modelView study →}.
Appetite: stimulates feeding in rats via CB1 — the opposite of CBD ^{3Reference 3Farrimond JA et al. · 2012AnimalCannabinol and cannabidiol exert opposing effects on rat feeding patterns — rat modelView study →}.
The honest headline: CBN’s strong-sedative reputation is not well supported; the effect looks real but small, and the “nature’s Ambien” framing outruns the data ^{1,2Reference 1Bonn-Miller MO et al. · 2024RCTA double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human)View study →Reference 2Arnold JC et al. · 2025AnimalA sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography modelView study →}.

0. Evidence by application

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Each application links to its write-up.

Application	Support	Rests on
Sleep	████░░░░░░ 42%	One small industry-funded human RCT (subjective) + objective rat polysomnography ^{1,2Reference 1Bonn-Miller MO et al. · 2024RCTA double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human)View study →Reference 2Arnold JC et al. · 2025AnimalA sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography modelView study →}
Appetite stimulation	███░░░░░░░ 35%	Rat feeding study; CB1-mediated ^{3Reference 3Farrimond JA et al. · 2012AnimalCannabinol and cannabidiol exert opposing effects on rat feeding patterns — rat modelView study →}

1. Sleep

The one human test is a double-blind RCT in 321 adults with poor sleep: 20 mg CBN nightly for a week modestly reduced night-time awakenings and overall sleep disturbance versus placebo, and adding CBD did not improve on CBN alone ^{1Reference 1Bonn-Miller MO et al. · 2024RCTA double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human)View study →}. The effect was small, industry-funded and on self-report. The best objective data are preclinical — a rat polysomnography study found CBN did increase total sleep (both NREM and REM) but in a biphasic pattern, and traced much of the effect to the metabolite 11-hydroxy-CBN, a far more potent CB1 agonist than CBN itself ^{2Reference 2Arnold JC et al. · 2025AnimalA sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography modelView study →}.

Gap: one small subjective human RCT plus rodent data — enough to suggest a real but modest effect, not the strong sedation CBN is marketed for, and the historical “sedative” lore came largely from THC-contaminated samples and THC-combination animal work, where CBN alone was weakly active ^{2,5Reference 2Arnold JC et al. · 2025AnimalA sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography modelView study →Reference 5Takahashi RN · 1975AnimalPharmacologic interaction between cannabinol and Δ9-tetrahydrocannabinol — animal modelView study →}.

2. Appetite stimulation

In satiated rats, oral CBN produced a CB1-receptor-mediated increase in appetite — shorter latency to feed and larger, longer meals — the mirror image of CBD’s appetite-suppressing effect ^{3Reference 3Farrimond JA et al. · 2012AnimalCannabinol and cannabidiol exert opposing effects on rat feeding patterns — rat modelView study →}.

Gap: rodent feeding behaviour only; no human appetite data ^{3Reference 3Farrimond JA et al. · 2012AnimalCannabinol and cannabidiol exert opposing effects on rat feeding patterns — rat modelView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Weak CB1 partial agonism	mild psychoactivity, appetite	appetite, sleep
Metabolism to 11-hydroxy-CBN (potent CB1 agonist)	likely carries much of the sedative effect	sleep
THC oxidation product	accumulates with age of the material	—

Clinical trials

CBN has a single completed sleep RCT and little else; interest is largely commercial, ahead of the clinical evidence.

Completed	Planned	Terminated	Preclinical
1 (sleep)	A few	—	Limited

Last checked: July 2026.

Toxicity & Safety

CBN is mildly active and regarded as well tolerated, with drowsiness the most commonly described effect. Because human study is minimal, its full safety profile and drug-interaction potential are not established — and since its effects appear partly mediated by a CB1-active metabolite, caution with other sedatives is sensible. Commercial CBN products vary in purity and labelled content, and some “CBN” on the market is simply aged/degraded THC material.

Pregnancy & lactation

Avoid (precautionary). No pregnancy or lactation safety data exist for CBN; as a cannabis constituent with weak CB1 activity it is prudent to avoid. Absence of studies is not evidence of safety.

Dosage

The only human dose with any evidence behind it is the 20 mg nightly used in the sleep RCT ^{1Reference 1Bonn-Miller MO et al. · 2024RCTA double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human)View study →} — a single, small, industry-funded study, so this is a studied dose, not a recommendation. No dose is established for any other use, and animal doses do not translate to humans.

References

Bonn-Miller MO, Feldner MT, Bynion TM, et al. (2024). A double-blind, randomized, placebo-controlled study of the safety and effects of CBN with and without CBD on sleep quality — randomised controlled trial (human). Experimental and Clinical Psychopharmacology. https://pubmed.ncbi.nlm.nih.gov/37796540/
Arnold JC, Occelli Hanbury-Brown CV, Anderson LL, et al. (2025). A sleepy cannabis constituent: cannabinol and its active metabolite influence sleep architecture in rats — rat polysomnography model. Neuropsychopharmacology. https://pubmed.ncbi.nlm.nih.gov/39528623/
Farrimond JA, Whalley BJ, Williams CM (2012). Cannabinol and cannabidiol exert opposing effects on rat feeding patterns — rat model. Psychopharmacology (Berl). https://pubmed.ncbi.nlm.nih.gov/22543671/
Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin — review. British Journal of Pharmacology. https://pubmed.ncbi.nlm.nih.gov/17828291/
Takahashi RN, Karniol IG (1975). Pharmacologic interaction between cannabinol and Δ9-tetrahydrocannabinol — animal model. Psychopharmacologia. https://pubmed.ncbi.nlm.nih.gov/168604/